BioSpace News Archive

Swedish Orphan Biovitrum AB presents data at the virtual ISTH 2021, the 29th Congress of the International Society on Thrombosis and Haemostasis, 17 – 21 July 2021.

Increasing focus of pharmaceutical companies on the development of advanced monoclonal antibodies is projected to help augment the growth of the global monoclonal antibodies market during the forecast period, set between 2020 and 2030.

Flow cytometry enables multi-parametric analysis of single cells in solution. The technology has enriched a vast body of studies of the immune system and numerous areas of cell biology.

Blood transfusion and Organ transplant is done to save the life of an individual or to improve patient’s health.

BioCopy AG announces a collaboration with Immatics N.V. “Immatics” in the field of characterization of T cell receptors.

RepliCel Life Sciences Inc. is pleased to announce it has submitted its application to Japan’s Ministry of Health, Labour, and Welfare for approval to manufacture the Company’s RCT-01 cell therapy for chronic tendinopathy and RCS-01 cell therapy for aging and sun-damaged skin for its upcoming clinical studies.

ViewRay, Inc. announced that the Miami Cancer Institute, part of Baptist Health South Florida, has enrolled the first patients in its “Stereotactic MRI-guided Adaptive Radiation Therapy in One Fraction for Inoperable Primary or Metastatic Carcinoma” clinical study – referred to as the SMART ONE trial.

Mallinckrodt plc, a global biopharmaceutical company, announced publication of results from the pivotal Phase 3 STRATA2016 clinical trial of StrataGraft®, which is approved for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated.

NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, announces it has raised an additional £20 million in a Series B2 financing round.

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced the expansion of its team through the addition of new employees to support business development, technical operations and certain strategic initiatives.